Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
FDA’s PreCheck Pilot Program aims to de-risk and accelerate domestic capacity buildouts via earlier regulatory interaction, aligning manufacturing policy with supply-chain resilience priorities.
A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...
In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
FDA selected seven participants from 80+ requests using a scoring rubric emphasizing supply need, facility development stage, time-to-market, and manufacturing innovation. Amneal will make sterile ...
In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, ...
Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results